Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat

Neuropharmacology

Volumn 50, Issue 6, 2006, Pages 761-768

  Taylor, Jennifer L ^a   Bishop, Christopher ^a   Ullrich, Thomas ^b   Rice, Kenner C ^b   Walker, Paul D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

D1 receptor; D2 receptor; Dyskinesia; M100907; Parkinson's disease; Supersensitivity

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; QUINPIROLE; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; HYPERKINESIA; INVOLUNTARY MOVEMENT; MALE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIAS; FLUOROBENZENES; FUNCTIONAL LATERALITY; LEVODOPA; MALE; OXIDOPAMINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; ROTAROD PERFORMANCE TEST; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 33646488703     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.12.004     Document Type: Article

References (62)

1. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16 (2001) 448-458
2. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., and Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 (2005) 17-26
3. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., and Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20 (2005) 932-936
4. Basura G.J., and Walker P.D. Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation. Brain Res. Dev. Brain Res. 116 (1999) 111-117
5. Basura G.J., and Walker P.D. Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion. Brain Res. Mol. Brain Res. 92 (2001) 66-77
6. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18 (1998) 5301-5310
7. Bishop C., Kamdar D.P., and Walker P.D. Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. Synapse 50 (2003) 164-170
8. Bishop C., and Walker P.D. Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience 121 (2003) 649-657
9. Bishop C., Daut G.S., and Walker P.D. Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 49 (2005) 350-358
10. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., and Mueller R.A. 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240 (1987) 167-176
11. Breese G.R., Napier T.C., and Mueller R.A. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J. Pharmacol. Exp. Ther. 234 (1985) 447-455
12. Cai G., Wang H.Y., and Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 302 (2002) 1105-1112
13. Campbell B.M., Gresch P.J., and Walker P.D. Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum. Neuroscience 105 (2001) 671-680
14. Corvol J.C., Muriel M.P., Valjent E., Feger J., Hanoun N., Girault J.A., Hirsch E.C., and Herve D. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 24 (2004) 7007-7014
15. Dekeyne A., Iob L., and Millan M.J. Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907. Neuropharmacology 44 (2003) 604-615
16. Delfino M.A., Stefano A.V., Ferrario J.E., Taravini I.R., Murer M.G., and Gershanik O.S. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav. Brain Res. 152 (2004) 297-306
17. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., and Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 (2004) 381-388
18. Filip M., Bubar M.J., and Cunningham K.A. Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J. Pharmacol. Exp. Ther. 310 (2004) 1246-1254
19. Friedman J.H., and Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 15 (2000) 201-211
20. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
21. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22 (2002) 5042-5054
22. Gomez-Mancilla B., and Bedard P.J. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 259 (1991) 409-413
23. Gresch P.J., and Walker P.D. Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease. Neuroscience 93 (1999) 831-841
24. Gresch P.J., and Walker P.D. Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat. Brain Res. Mol. Brain Res. 70 (1999) 125-134
25. Grondin R., Doan V.D., Gregoire L., and Bedard P.J. D1 receptor blockade improves l-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52 (1999) 771-776
26. Hall H., Kohler C., and Gawell L. Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur. J. Pharmacol. 111 (1985) 191-199
27. Harrison M.B., Wiley R.G., and Wooten G.F. Selective localization of striatal D1 receptors to striatonigral neurons. Brain Res. 528 (1990) 317-322
28. Hyttel J. SCH 23390 - the first selective dopamine D-1 antagonist. Eur. J. Pharmacol. 91 (1983) 153-154
29. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., van Giersbergen P.L., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277 (1996) 968-981
30. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 (1996) 116-124
31. Kilpatrick I.C., Jones M.W., and Phillipson O.T. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46 (1986) 1865-1876
32. Kostrzewa R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19 (1995) 1-17
33. Laprade N., Radja F., Reader T.A., and Soghomonian J.J. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J. Neurosci. 16 (1996) 3727-3736
34. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
35. Lucas G., and Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74 (2000) 693-701
36. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
37. Maertens de Noordhout A., and Delwaide P.J. Open pilot trial of ritanserin in parkinsonism. Clin. Neuropharmacol. 9 (1986) 480-484
38. McMahon L.R., and Cunningham K.A. Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J. Pharmacol. Exp. Ther. 297 (2001) 357-363
39. Meco G., Marini S., Lestingi L., Lifante I., Modarelli F.T., and Agnoli A. Controlled single-blind crossover study of ritanserin and placebo in l-DOPA-induced dyskinesias in Parkinson's disease. Curr. Ther. Res. 43 (1988) 262-270
40. Meco G., Fabrizio E., Alessandri A., Vanacore N., and Bonifati V. Risperidone in levodopa induced dyskinesiae. J. Neurol. Neurosurg. Psychiatry 64 (1998) 135
41. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
42. Moser P.C., Moran P.M., Frank R.A., and Kehne J.H. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav. Brain Res. 73 (1996) 163-167
43. Numan S., Lundgren K.H., Wright D.E., Herman J.P., and Seroogy K.B. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res. 29 (1995) 391-396
44. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 (1990) 340-345
45. O'Boyle K.M., Gaitanopoulos D.E., Brenner M., and Waddington J.L. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology 28 (1989) 401-405
46. Oh J.D., Bibbiani F., and Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 177 (2002) 557-564
47. O'Neill M.F., Heron-Maxwell C.L., and Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav. 63 (1999) 237-243
48. Paxinos G., and Watson W. The Rat Brain in Stereotaxic Coordinates. fourth ed. (1998), Academic Press, San Diego
49. Pifl C., Nanoff C., Schingnitz G., Schutz W., and Hornykiewicz O. Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 1997-2004
50. Pollack A.E., and Yates T.M. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats. Neuroscience 94 (1999) 505-514
51. Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdere P., Caccia S., Esposito E., and Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 (2002) 311-324
52. Radja F., Descarries L., Dewar K.M., and Reader T.A. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res. 606 (1993) 273-285
53. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 (2000) 1484-1491
54. Rascol O., Nutt J.G., Blin O., Goetz C.G., Trugman J.M., Soubrouillard C., Carter J.H., Currie L.J., Fabre N., Thalamas C., Giardina W.W., and Wright S. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol. 58 (2001) 249-254
55. Schmidt C.J., Fadayel G.M., Sullivan C.K., and Taylor V.L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223 (1992) 65-74
56. Schmidt C.J., Sullivan C.K., and Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62 (1994) 1382-1389
57. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
58. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., and Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266 (1993) 684-691
59. Taylor J.L., Bishop C., and Walker P.D. Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 81 (2005) 887-893
60. Tsuruta K., Frey E.A., Grewe C.W., Cote T.E., Eskay R.L., and Kebabian J.W. Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292 (1981) 463-465
61. Ullrich T., and Rice K.C. A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands. Bioorg. Med. Chem. 8 (2000) 2427-2432
62. Vickers S.P., Easton N., Malcolm C.S., Allen N.H., Porter R.H., Bickerdike M.J., and Kennett G.A. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol. Biochem. Behav. 69 (2001) 643-652